JP2015502352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015502352A5 JP2015502352A5 JP2014542593A JP2014542593A JP2015502352A5 JP 2015502352 A5 JP2015502352 A5 JP 2015502352A5 JP 2014542593 A JP2014542593 A JP 2014542593A JP 2014542593 A JP2014542593 A JP 2014542593A JP 2015502352 A5 JP2015502352 A5 JP 2015502352A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- alcohol
- malignant
- perillyl alcohol
- patent document
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NDTYTMIUWGWIMO-UHFFFAOYSA-N perillyl alcohol Chemical compound CC(=C)C1CCC(CO)=CC1 NDTYTMIUWGWIMO-UHFFFAOYSA-N 0.000 description 16
- 229930007631 (-)-perillyl alcohol Natural products 0.000 description 8
- 235000005693 perillyl alcohol Nutrition 0.000 description 8
- 206010018338 Glioma Diseases 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 208000029824 high grade glioma Diseases 0.000 description 3
- 201000011614 malignant glioma Diseases 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 229930003658 monoterpene Natural products 0.000 description 2
- 150000002773 monoterpene derivatives Chemical class 0.000 description 2
- 235000002577 monoterpenes Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- NDTYTMIUWGWIMO-SNVBAGLBSA-N (-)-perillyl alcohol Chemical compound CC(=C)[C@H]1CCC(CO)=CC1 NDTYTMIUWGWIMO-SNVBAGLBSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- -1 for example Chemical compound 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161562105P | 2011-11-21 | 2011-11-21 | |
| US61/562,105 | 2011-11-21 | ||
| US13/566,731 | 2012-08-03 | ||
| US13/566,731 US8916545B2 (en) | 2010-08-27 | 2012-08-03 | Pharmaceutical compositions comprising POH derivatives |
| PCT/US2012/066379 WO2013119304A2 (en) | 2011-11-21 | 2012-11-21 | Pharmaceutical compositions comprising deuterium-enriched perillyl alcohol, iso-perillyl alcohol and derivatives thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017161091A Division JP2018035148A (ja) | 2011-11-21 | 2017-08-24 | 重水素強化ペリリルアルコール、イソペリリルアルコール、及びその誘導体を含む医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015502352A JP2015502352A (ja) | 2015-01-22 |
| JP2015502352A5 true JP2015502352A5 (enExample) | 2015-11-26 |
Family
ID=48948152
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014542593A Pending JP2015502352A (ja) | 2011-11-21 | 2012-11-21 | 重水素強化ペリリルアルコール、イソペリリルアルコール、及びその誘導体を含む医薬組成物 |
| JP2017161091A Pending JP2018035148A (ja) | 2011-11-21 | 2017-08-24 | 重水素強化ペリリルアルコール、イソペリリルアルコール、及びその誘導体を含む医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017161091A Pending JP2018035148A (ja) | 2011-11-21 | 2017-08-24 | 重水素強化ペリリルアルコール、イソペリリルアルコール、及びその誘導体を含む医薬組成物 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2782894A4 (enExample) |
| JP (2) | JP2015502352A (enExample) |
| KR (1) | KR20150000469A (enExample) |
| CN (1) | CN103946202A (enExample) |
| BR (1) | BR112014012180A2 (enExample) |
| CA (1) | CA2856403A1 (enExample) |
| HK (1) | HK1201253A1 (enExample) |
| WO (1) | WO2013119304A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012083178A1 (en) * | 2010-12-17 | 2012-06-21 | Neo Oncology Inc. | Methods and devices for using isoperillyl alcohol |
| CN104945334B (zh) * | 2014-03-27 | 2018-02-16 | 沈阳药科大学 | 紫苏醇衍生物及其制备和应用 |
| CN104945335B (zh) * | 2014-03-27 | 2018-02-16 | 沈阳药科大学 | 紫苏胺类化合物及其制备和应用 |
| CN104945333B (zh) * | 2014-03-27 | 2018-02-02 | 沈阳药科大学 | 紫苏醇类似物及其制备和应用 |
| CN104945336B (zh) * | 2014-03-27 | 2018-02-16 | 沈阳药科大学 | 紫苏酸甲酯含氮衍生物及其制备和应用 |
| BR112020016074A2 (pt) | 2018-02-08 | 2020-12-08 | Neonc Technologies, Inc | Métodos de permeabilização da barreira hematoencefálica |
| CN116789530B (zh) * | 2023-05-16 | 2025-12-19 | 杭州师范大学 | 一种紫苏醇酚类衍生物及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4272441A (en) * | 1980-03-13 | 1981-06-09 | Fmc Corporation | Preparation of carbamates |
| JP4634694B2 (ja) * | 2001-03-23 | 2011-02-16 | ルイトポルド・ファーマシューティカルズ・インコーポレーテッド | 脂肪アルコール薬物複合体 |
| WO2003057193A1 (en) * | 2001-12-11 | 2003-07-17 | Dor Biopharma, Inc. | Monoterpene compositions and uses thereof |
| BR0107262B1 (pt) | 2001-12-17 | 2014-04-22 | Da Fonseca Clovis Orlando Pereira | Composição farmacêutica inalatória |
| US20060014732A1 (en) * | 2004-06-23 | 2006-01-19 | Hofmann Robert F | Use of targeted oxidative therapeutic formulation in treatment of burns |
| US7601355B2 (en) | 2005-06-01 | 2009-10-13 | Northwestern University | Compositions and methods for altering immune function |
| WO2008062466A2 (en) * | 2006-10-13 | 2008-05-29 | Reliance Life Sciences Pvt. Ltd. | Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer |
| EP3620154A1 (en) * | 2009-02-06 | 2020-03-11 | University Of Southern California | Therapeutic compositions comprising monoterpenes |
| ES2600928T3 (es) * | 2010-08-27 | 2017-02-13 | Neonc Technologies Inc. | Composiciones farmacéuticas que comprenden derivados de alcohol perilílico |
| CN101979378B (zh) * | 2010-10-13 | 2012-06-27 | 中国科学院上海有机化学研究所 | 一种手性γ-内酰胺化合物的合成方法 |
-
2012
- 2012-11-21 WO PCT/US2012/066379 patent/WO2013119304A2/en not_active Ceased
- 2012-11-21 CN CN201280057166.6A patent/CN103946202A/zh active Pending
- 2012-11-21 JP JP2014542593A patent/JP2015502352A/ja active Pending
- 2012-11-21 BR BR112014012180A patent/BR112014012180A2/pt not_active IP Right Cessation
- 2012-11-21 HK HK15101876.0A patent/HK1201253A1/xx unknown
- 2012-11-21 CA CA2856403A patent/CA2856403A1/en not_active Abandoned
- 2012-11-21 EP EP12867815.8A patent/EP2782894A4/en not_active Withdrawn
- 2012-11-21 KR KR20147016865A patent/KR20150000469A/ko not_active Withdrawn
-
2017
- 2017-08-24 JP JP2017161091A patent/JP2018035148A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014505008A5 (enExample) | ||
| JP6539345B2 (ja) | がん治療のための医薬組成物の調製におけるデュロキセチン塩酸塩薬物の使用 | |
| JP2021073310A (ja) | Ｒ−ケタミンおよびその塩の医薬品としての応用 | |
| NI201300082A (es) | Métodos de tratamiento del cáncer utilizando 3 - ( 5 - amino - 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il ) - piperidin - 2, 6 - diona. | |
| JP2014507391A5 (enExample) | ||
| RU2010143864A (ru) | Способы лечения нарушений с применением селективного антагониста nr2b-подтипа nmda рецепторов | |
| UA109698C2 (xx) | Похідні азаіндазолу або діазаіндазолу як медикамент | |
| BR112013009004A2 (pt) | combinações de agonistas de receptor de serotonina para o tratamento de distúrbios de movimento | |
| Ning et al. | Novel hybrid conjugates with dual suppression of estrogenic and inflammatory activities display significantly improved potency against breast cancer | |
| CN106660974A (zh) | 含氨磺酰基的1,2,5‑噁二唑类衍生物、其制备方法及其在医药上的应用 | |
| Gan et al. | Effect of esketamine on postoperative depressive symptoms in patients undergoing thoracoscopic lung cancer surgery: a randomized controlled trial | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| EA201171087A1 (ru) | СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ | |
| JP2015519347A5 (enExample) | ||
| Collina et al. | Are sigma modulators an effective opportunity for cancer treatment? A patent overview (1996-2016) | |
| CY1118158T1 (el) | Δευτεριωμενα 1-πιπεραζινο-3-φαινυλικα ινδανια για τη θεραπευτικη αντιμετωπιση της σχιζοφρενιας | |
| JP2014530181A5 (enExample) | ||
| Zhang et al. | Clinical benefits and challenges of esketamine in elderly patients during the perioperative period | |
| Shahani | Tramadol precipitating serotonin syndrome in a patient on antidepressants | |
| Huang et al. | Coadministration of β‐asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: A different mechanism from M adopar | |
| EA201400761A1 (ru) | Производные 1,3-дифенилпропана, их получение и применение | |
| IN2014KN01113A (enExample) | ||
| JP2018530612A5 (enExample) | ||
| Mao et al. | Role of 5-HT1A and 5-HT1B receptors in the antidepressant-like effect of piperine in the forced swim test | |
| Sidhu et al. | Oral choline supplementation for postoperative pain |